For both melanoma and multiple myeloma we are continuously expanding the program in order to make a broad array of diagnostic tools available that address a high unmet medical need for cancer patients. Disclosed pipeline additions for multiple myeloma are treatment prediction markers and for melanoma a prognostic marker, developed within the Peregrine Study Initiative. Follow this link to find more information on the Peregrine Study Initiative.
In September 2020, we have announced our collaboration with Imperial College London and the University of California San Diego School of Medicine, for the joint development of a diagnostic test that will facilitate early diagnosis of Kawasaki Disease. A rare, acute inflammatory disease with an unknown origin that causes inflammation of arteries, particularly in the heart, and predominantly affects infants and children below 5 years of age. Follow this link to the press release and related peer-reviewed discovery paper.
Biomarker Discovery Services
While most biomarker discovery projects under Strix Services are undisclosed. We have announced in March 2020 an agreement with public biopharmaceutical company BioInvent International AB (OMXS: BINV) to characterize the gene expression and immunological signatures in tumors of patients pre- and post-treatment with BI-1206. Follow this link for the press release and related information. Click here for more information on Strix Services for biomarker discovery.